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Abstract
In December 2019, a new coronavirus, now labeled as severe acute respiratory syndrome coronavirus 2, induced 
an episode of acute atypical respiratory illness started in Wuhan, Province of Hubei, China. The illness triggered by 
this virus was called coronavirus disease-19 (COVID-19). The infection is spread within humans and has triggered 
a global pandemic. The amount of death tolls continues to increase and a growing number of countries have been 
driven to create social barriers and lock-ups. The shortage of tailored counseling remains an issue. Epidemiological 
researches have shown that elderly patients are more vulnerable to serious diseases, while children tend to have 
milder symptoms. Here, we checked the latest understanding of this disease and found a possible explanation of the 
potential sequel and the expectations for the future.
Introduction
On the morning of 1 day, the world will not 
wake up to a message, phone, or urgent news that 
the crisis is over and the ponds of the pandemic have 
all receded in one go [1]. It is essential that no one 
knows when the ordeal of humanity will end with 
the emerging coronavirus “coronavirus disease-19 
(COVID 19)” with certainty [2]. In spite of the 
optimistic visions that herald the diminishing fears 
and decreasing the growing losses currently, other 
visions and analyses are expecting the worse for a 
year coming or over [3].
The problem that closes all doors of 
anticipation is that the current crisis is not a war that 
could end with a truce or a peace agreement, and 
not a recession or economic distress that is sufficient 
for countries to allocate an urgent support and 
revitalization package [4]. The world is locked in a 
struggle with an eccentric microscopic organism, for 
which complete information is not yet available, so it is 
difficult to surround the stakes of the crisis or to predict 
the behaviors of the virus, and all we have until now: 
A map of actions and measures, a list of expectations 
and possibilities, and an open horizon on hopes, 
aspirations, and fears that are not completely negative, 
and it is not guaranteed to reach its positive points in 
time [5], [6].
Rapid Pandemic and Mysterious 
Organism
Even now, the picture is not entirely clear, even 
among specialists from doctors and microbiologists. 
The most alarming thing about the crisis is that the new 
coronavirus “COVID 19” has disturbing characteristics 
in terms of proliferation, infection, and periods of 
survival outside living cells, and the most disturbing is 
that the virus is mysterious for us, so what we know 
about it is much less than what we do not know [6], [7]. 
Fears are compounded by preliminary weightings from 
researchers and doctors that involve the possibility 
that this huge unknown area is dynamic, that is, it is a 
changing state in terms of characteristics and activity, 
and not a constant that can build the equation on it 
and reach a sound solution to it due to the ability to 
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control the variables associated with the pathology or 
the conditions of transmission and yet infection [7].
On January 2020, the World Health Organization 
said it had no evidence of transmission of “COVID 19” 
between humans, indicating that it may differ from the 
well-known Corona family, including the severe acute 
respiratory syndrome (SARS) and Middle East respiratory 
syndrome viruses, or that it is closer to the “Hantavirus” 
family, which is transmitted from rodents to humans, but 
not between humans and each other [7], [8]. The important 
thing is that the aforementioned health statement pushed 
many countries to a state of reassurance and caused the 
delay in adopting serious measures to confront, to the 
extent that many parties now accuse the organization of 
being the reason behind the spread of the epidemic [8].
Political Versus Medical Point of View
The US President announced in his daily 
briefing that his country decided to suspend its regular 
support to the World Health Organization (Washington is 
the largest contributor to the budget of the International 
Organization), because it provides false information 
about the emerging epidemic of coronavirus, according 
to his statement [9]. Beyond the possibilities of political 
recruitment, whether in his speech, or accusing the 
organization of bias toward China, or even accusing 
China itself of blinding and concealing facts, the only 
thing that is reached is that the current epidemic 
represents a real danger, first because it is evil and 
rapidly spreading and second because we are unable 
to understand and surround it until now, and most 
importantly, we were not prepared for this type of long-
term crisis, and that point alone will cause confusion in 
plans and prolong the ordeal [10].
Current Precautions versus Curfews and 
Panic
Actually, we are facing an “INFODEMIC” 
rather than a pandemic. Previous reports stated that 
the virulence and infectivity of measles, smallpox, and 
SARS were more than COVID-19, 15 times, 10 times, 
and 3 times, respectively. Case fatality in Ebola virus 
is 6 times higher than COVID 19. Reports stated that 
many points of weakness in the virus-like inability of the 
virus to be transmitted and survive in high temperatures, 
which means a high possibility of cessation in the 
summer season. Global panic and massive vibrations 
in social media will only make the problem worse [11].
Prisoning of people at homes and 24 h curfews 
will not participate in problem solving. On contrary, it 
may lead to other problems such as depression, anxiety, 
obesity, suicidal attempts, moreover, the economic and 
financial crisis at the individual and community level. 
Like it or not, a day will come, when the international 
systems will collapse, and the governments will be 
forced to leave people to confront the virus with simple 
precautions and personal immunity [12].
Simple precautions and well-cultured people 
are enough to stop the virus. Handwashing, masks, 
gloves, and practicing of proper social distancing can 
safely replace curfews and panic. Governments can 
prevent the crowd by closing malls and social clubs, not 
by prisoning people at homes. Prevent the places of 
crowdedness but not prison people [13].
When does the Epidemic Stop?
Despite touching the level of a million and a 
half infections, in 4 months, and recording about 85,000 
deaths, which exceeds 5.6%, with a spread in more 
than 212 countries and regions around the world, it 
cannot be said that we have reached the peak level so 
far [13]. The World Health Organization says that most 
countries in the world do not provide true and accurate 
figures on infections, and Italian press reports indicated 
that the analysis of the blood of healthy donors in one of 
the affected towns of the Lombardy region had proven 
the presence of antibodies to the virus in 70% of them. 
Whether this information is correct or not, it is certain 
that the actual infections are more than what the health 
services calculate around the world [14].
The previous truth may seem reassuring to 
some when approaching the scene and trying to foresee 
its future horizons, as the underlying meaning is that 
the epidemic is not necessarily dangerous and deadly 
for everyone and that thousands or millions of people 
crossed it without feeling or feeling their country [15]. 
However, unlike that optimistic case, the matter is not 
reassuring, first because we do not know the virus fully, 
and then we have no evidence that it may not return or 
that those who recovered from it are immune from its 
recurrence again and second because we do not know 
these potential cured patients. So by default, all of us 
remain in existing danger even for those who were not 
aware that they were infected and recovered [16].
The most dangerous thing is that even if the 
real numbers are a 1000 times the numbers currently 
registered, this does not represent only 20% of the 
world’s population, and the extent of the epidemic is 
still open to 6 billion people who could be infected in the 
future near. In practice, the cessation of the epidemic 
is not related to any precautionary measures. Rather, 
it could be a reason for the complexity of the crisis in 
the future [17]. The global economy does not bear the 
broad and long-term closure, and health institutions 
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cannot work with that operational power and the pace 
indefinitely, and at some point, everyone may have to 
reduce the oppressive grip of the epidemic circumstance, 
which may cause an explosion or an acute wave of 
infections with a more massive bill because it comes 
after the economy and state structures have been 
completely exhausted [18].
The calculations are all complicated, and in 
a simple way, it can be said that the epidemic stop 
station is linked to biological inputs that cannot be 
induced or predicted, and the stage of its decline or its 
transformation into a transient seasonal disease will not 
be achieved before acquiring a wide-ranging societal 
immunity (at least 60% of people) [19]. It means that 
nearly 5 billion should be infected and recovered from 
the virus or acquires the virus without infection [20].
The Pessimistic Hypothesis
The optimistic forecasts hope that the crisis will 
pass within weeks, whether due to high temperatures 
and droughts during the summer or with metaphysical 
hopes that the infection will decline, even if the scientific 
opinion so far has been the opposite [21]. Pessimistic 
expectations not only indicate the continuation of the 
epidemic beyond the middle of next year only but augur 
well for its renewal in fierce epidemiological waves for 
several years before it subsides and takes a simple 
seasonal form, just like the current flu [22]. Between the 
two possibilities, scientists stand without the ability to 
resolve the matter yet [23].
Almost and approximately every hundred years, 
the universe has been attacked fiercely by a wave of 
an influenza pandemic [24], [25]. The last one was the 
Spanish flu pandemic in 1918, which was responsible 
for the mortality of 50 million of people over <10 
years [26], [27]. Until it has been transformed to what’s 
known nowadays by seasonal influenza, which used to 
come to everyone every year without significant side 
effects [28], [29]. This could be due to the adaptation of 
the human immunity for this virus across human being 
generations [30], [31]. According to this hypothesis 
and according to the pessimistic view, the outcome of 
the previous pandemic will be achieved by the current 
pandemic, with one difference [32], [33]. The number of 
mortalities will not reach 50 million in 10 years, but in 
30–50 years because of the exaggerated precautions 
and curfews [34], [35]. This could be like some sort of 
natural selection [36], [37]. Family of influenza viruses 
characterized by periodic genetic mutation in the form 
antigenic shifts, every 10 years, and antigenic drifts 
every year [38], [39].
What we are going through today is one 
of the severest antigenic shifts of the influenza 
virus [40], [41]. Almost a new inscrutable virus not used 
to be transmitted from human to human [42], [43]. It 
was only a zoonotic cycle and man is not involved 
except by viral mutation [44], [45]. Our target is to 
elicit a natural active immunity in the whole population 
through allowing of subclinical/clinical infections and 
herd immunity [46], [47]. From the beginning of the 
pandemic, the countries which applied strict 24 h 
curfew have shown no decrease in case numbers on 
the epidemic curve [48], [49]. After curfew practicing, 
the cases continued to increase [50], [51]. The 
number of cases detected as well as fatalities in 
underdeveloped countries which did not apply any 
precautions was less than developed countries who 
applied strict precautions [52], [53]. This may be due 
to lack of modern diagnostic technology or may be due 
to the high population immunity or may be due to herd 
immunity acquired by the spread of subclinical infection 
all over the nation, no one knows [54], [55].
The Epidemic between, Medicine and 
Vaccine
To this moment, the SARS Cove 2 mutations 
or the emerging COVID 19 have not yet been 
severed [56], [57]. The main host of the virus is the 
bat that has a huge reservoir of that viral family, but 
the human infection did not come from a bat [58], [59]. 
China said that the virus was transmitted to humans 
from an anteater with a squid ant, but available studies 
indicated a similarity observation of about 94% with 
the possible validity of that [60], [61]. The information, 
however, cannot be confirmed, and until the moment 
also, information is conflicting about the “zero” case, 
which was the first human infection, and many Chinese 
media outlets published reports on more than three 
people as the first infection [62], [63].
In contrast, studies varied regarding the 
periods of virus activity outside the host cells and on 
different surfaces, and some said that it is transmitted 
in the air, and doctors differed in the clinical symptoms 
of patients, and the response to health care varied even 
with the installation of variables of geography, weather, 
age, and patient history [64], [65]. In short, we do not 
yet know “COVID 19” as it should, and by default, our 
predictions about it cannot be completely accurate 
unless we have more cases, more basic research, and 
no fear to face [66], [67]. We must give up the dread 
and have the courage to know more about the virus, not 
just follow the precautions for fear of infection [68], [69].
Access to an effective drug in the face of 
clinical symptoms, mitigating the effects of the virus 
and then curing it can be an important step toward 
reducing the severity of the epidemic and escaping 
from its economic, political, and psychological 
repercussions, and reaching a “vaccine” can lead to a 
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state of reassurance, stability, and ability to restore an 
aspect of natural daily life, at least in the vital sectors 
and productive institutions [70]. Contrary to positive 
expectations committed to logic, or hopes driven by the 
state of fear and the search for reassurance, even if they 
are false, the medicine and vaccine will not be the end 
of the epidemic as some people think, not because they 
will miss the effectiveness in facing it and restraining it, 
but because the equations of testing, production, and 
sufficiency have its pressures, and most importantly, 
the crisis is not a war that stops its fire completely with 
armistice or surrender of the virus under the bombing of 
laboratories and drug factories [71].
Gradual Exit and Extended Effects
At present, world leaders and experts sit 
inside laboratories and hospitals [72]. Everyone thinks 
that the crisis will not end far away from epidemiology, 
microbiology, and pharmacology, but most likely they 
will move away from a little, not beyond the horizons of 
scientific solutions, but rather close to the panoramic 
view and integrated solutions that balance the 
considerations of science and economics with the lives 
and lives of people [73]. Decision-makers must leave 
their offices and go down to the ground to reconsider 
the planning of streets and squares [74]. Doctors, 
scientists, and researchers will work on their important 
path, but others will turn to idle paths, but they are 
equally important [75].
Many societies will gradually return to 
life, with strict precautions and a constant level of 
fear [76]. Perhaps Germany’s pathway to conducting 
immunological examinations and tests and allowing 
those who are found to be less at risk to return to work 
and re-pump blood into the arteries of the economy 
may be adopted [77]. That vision may expand or be 
circulated temporarily, especially since even with the 
arrival of a guaranteed drug or an effective vaccine, the 
crisis will not end immediately, fears will remain, and the 
potential for risk will be open until the epidemiological 
freeze is confirmed, to begin the chain of gradual 
decline associated with the priority of countries and 
sectors and who are getting on innovative drugs and 
return to a normal life first [78].
The economic and social effects of the 
epidemic, the state of panic and psychological fractures 
that have afflicted millions of people around the world, 
confirm that the virus sizing or drug suppression station 
will not be the end of the crisis [79]. It will take months 
to restore the psyche of those affected and longer 
months to repair the economic cracks and perhaps 
years to restore confidence in the existing global 
system and people return to a full normal life [80]. 
The first periods will witness confusion in visions, 
evil demand for goods and services, a sharp rise in 
prices with diminishing savings and benefits, and the 
ability of banking institutions to activate the investment 
machine [81]. Those potential prospects mean that the 
pace of exiting the repercussions of the crisis may be 
slower than overcoming the epidemic itself and that we 
may live as “COVID 19” fears and its effects for years 
to come, even if we close the epidemic page a year 
later as pessimists expect, or within weeks as optimists 
preach [82].
Conclusion
Our vision for the current situation could be 
summarized in the following points; the most affected 
categories are diabetic patients and those who were 
immunocompromized. Most of cases are subclinical 
infection and the disease transmitted among people 
by herd immunity. No need for exaggerated or 
arbitrary measures, just infection control precautions, 
immunity augmentation, and treatment of diabetes. 
we recommend the conduction of studies to prove that 
medical staff who were positive for COVID 19, didn’t 
know about their disease except at the time of study.
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